Prevention of CMV disease after kidney transplantation

Prevention of CMV disease after kidney transplantation refers to proactive pharmacological intervention aimed at averting primary infection or reactivation of human cytomegalovirus in renal allograft recipients maintained on therapeutic immunosuppression In this vulnerable immunocompromised population—particularly high-risk seronegative recipients receiving an organ from a seropositive donor (D+/R−)—uncontrolled viral replication can manifest clinically as CMV syndrome with systemic symptoms suc...

Prevention of CMV disease after kidney transplantation refers to proactive pharmacological intervention aimed at averting primary infection or reactivation of human cytomegalovirus in renal allograft recipients maintained on therapeutic immunosuppression In this vulnerable immunocompromised population—particularly high-risk seronegative recipients receiving an organ from a seropositive donor (D+/R−)—uncontrolled viral replication can manifest clinically as CMV syndrome with systemic symptoms suc...

Prevention of CMV disease after kidney transplantation refers to proactive pharmacological intervention aimed at averting primary infection or reactivation of human cytomegalovirus in renal allograft recipients maintained on therapeutic immunosuppression

In this vulnerable immunocompromised population—particularly high-risk seronegative recipients receiving an organ from a seropositive donor (D+/R−)—uncontrolled viral replication can manifest clinically as CMV syndrome with systemic symptoms such as fever, malaise, cytopenias, and transaminitis, or progress to tissue-invasive disease involving the gastrointestinal tract, lungs, or allograft itself

In this vulnerable immunocompromised population—particularly high-risk seronegative recipients receiving an organ from a seropositive donor (D+/R−)—uncontrolled viral replication can manifest clinically as CMV syndrome with systemic symptoms such as fever, malaise, cytopenias, and transaminitis, or progress to tissue-invasive disease involving the gastrointestinal tract, lungs, or allograft itself

Prophylactic strategies are designed to inhibit viral DNA synthesis, thereby decreasing the risk of end-organ damage, acute or chronic graft rejection, and infection-associated mortality

Prophylactic strategies are designed to inhibit viral DNA synthesis, thereby decreasing the risk of end-organ damage, acute or chronic graft rejection, and infection-associated mortality